On April 23, 2026, Roche Holding AG (SWX: ROG) reported first-quarter sales growth of 6% at constant exchange rates, driven by strong demand for oncology and immunology products, whereas reported sales in Swiss francs declined 5% due to the franc’s 11% year-to-date appreciation against the euro and dollar, aligning with analyst forecasts and underscoring the persistent impact of currency volatility on multinational pharma earnings.
The Bottom Line
- Roche’s Q1 2026 constant-currency sales growth of 6% exceeded the 5.2% consensus estimate, reflecting resilient demand for key oncology drugs like Hemlibra and Tecentriq despite pricing pressures in mature markets.
- The 5% decline in CHF-reported sales was primarily attributable to the Swiss franc’s strength, which reduced the franc-value of foreign earnings by approximately CHF 1.8 billion in Q1 alone, a headwind not fully offset by pricing or volume gains.
- Roche reaffirmed its 2026 full-year guidance of low-to-mid single-digit constant-currency sales growth and core EPS growth of 8–10%, signaling confidence in its pipeline execution and cost discipline amid macroeconomic uncertainty.
Currency Headwinds Mask Underlying Operational Strength in Roche’s Q1 Performance
While the headline CHF-declined sales figure may raise initial concerns, the constant-currency metric reveals a more nuanced picture: Roche’s pharmaceutical division grew 5% at CER, led by a 12% rise in oncology sales and a 9% increase in immunology, particularly driven by U.S. And European demand for Hemlibra in hemophilia and Alecensa in lung cancer. Diagnostics sales rose 8% at CER, supported by strong performance in centralized testing and point-of-care solutions. These gains were partially offset by a 3% decline in viral testing demand compared to the elevated 2025 baseline, a predictable normalization as pandemic-related testing volumes recede.
According to Roche’s Q1 2026 financial report, the company generated CHF 15.2 billion in revenue, with CHF 11.4 billion from Pharmaceuticals and CHF 3.8 billion from Diagnostics. At constant exchange rates, Pharmaceuticals revenue reached CHF 12.1 billion and Diagnostics CHF 4.1 billion. The CHF 1.8 billion currency-related drag was driven by the franc’s average exchange rate of 0.92 CHF/EUR and 0.88 CHF/USD in Q1 2026, compared to 0.98 and 0.94, respectively, in Q1 2025.
Market Reaction and Competitive Positioning in the Global Pharma Landscape
Following the announcement, Roche’s shares traded flat on the SIX Swiss Exchange, reflecting investor acceptance of the forex-driven headline miss amid confirmation of underlying growth. In contrast, Novartis (SWX: NOVN) reported Q1 constant-currency sales growth of 4%, lagging Roche’s pace, while AstraZeneca (LON: AZN) delivered 7% CER growth, buoyed by stronger oncology performance in emerging markets. The divergence highlights Roche’s relative strength in immunology and its diversified diagnostics franchise, which provides a buffer against pharmaceutical pricing pressures.
Analysts at UBS noted that Roche’s ability to maintain mid-single-digit CER growth despite pricing headwinds in the U.S. Medicare Part D market and European reference pricing reforms demonstrates the durability of its patent-protected portfolio. “Roche’s immunology franchise, particularly Hemlibra, is showing pricing resilience that many peers lack,” said a senior healthcare analyst at UBS during a post-earnings call.
“What’s impressive is not just the growth, but the quality of it — Roche is gaining share in high-barrier therapeutic areas where biosimilar competition remains limited.”
Meanwhile, the stronger franc has prompted renewed debate over Switzerland’s monetary policy stance. The Swiss National Bank (SNB) has maintained its policy rate at 1.5% since March 2025, citing inflation near target and cautious wage growth. Though, the franc’s appreciation has intensified pressure on export-oriented industries, with the SNB intervening sporadically in foreign exchange markets to prevent excessive volatility. Economists at Credit Suisse estimate that a 10% sustained franc appreciation reduces Swiss industrial GDP growth by approximately 0.4 percentage points annually, a headwind that extends beyond pharma to machinery, watchmaking, and commodities trading.
Forward Guidance and Capital Allocation Strategy
Roche reiterated its 2026 outlook, projecting constant-currency sales growth of 4–6% and core EPS growth of 8–10%, underpinned by continued launches of modern indications for existing drugs (e.g., Tecentriq in early-stage lung cancer) and incremental contributions from its Phase III pipeline. The company expects to return CHF 10–12 billion to shareholders via dividends and buybacks in 2026, maintaining a payout ratio of approximately 60% of core net income.
Capital expenditure remains focused on biologics manufacturing capacity, with CHF 2.1 billion allocated for facility expansions in Singapore, the U.S., and Germany. Roche also announced a CHF 300 million increase in its venture capital arm, Roche Ventures, to support early-stage investments in cell therapy and AI-driven drug discovery — a move mirrored by peers like Merck KGaA and GSK, which have similarly expanded their external innovation budgets in response to declining internal R&D productivity.
Comparative Financial Performance: Roche Q1 2026 vs. Peers
| Company | Q1 2026 Sales (Constant Currency) | Q1 2026 Sales (Reported Currency) | Currency Impact | Market Cap (as of Apr 22, 2026) |
|---|---|---|---|---|
| Roche Holding AG (SWX: ROG) | +6.0% | -5.0% | -11.0 pp | CHF 285 billion |
| Novartis AG (SWX: NOVN) | +4.0% | -3.5% | -7.5 pp | CHF 198 billion |
| AstraZeneca PLC (LON: AZN) | +7.0% | +2.0% | -5.0 pp | GBP 165 billion |
| Merck &. Co. (NYSE: MRK) | +5.5% | +1.0% | -4.5 pp | USD 290 billion |
Source: Company reports, Bloomberg, SIX Group, LSEG Data & Analytics. Currency impact calculated as the difference between constant-currency and reported sales growth percentages.
Macroeconomic Context and Implications for Global Health Equity
Roche’s performance underscores the growing disconnect between operational strength and reported financials in a currency-volatile environment, particularly for Swiss-based multinationals. The franc’s strength, driven by safe-haven inflows amid persistent geopolitical uncertainty and divergent monetary policies between the SNB, ECB, and Fed, has created a structural headwind for Swiss exporters that is unlikely to reverse in the near term.
This dynamic has broader implications: as pharmaceutical companies face increasing pressure to absorb currency losses without raising prices in regulated markets, incentives to shift manufacturing and R&D activities to lower-cost jurisdictions may intensify. Roche has already expanded its biologics production in Singapore and the U.S., a trend that could accelerate if the franc remains strong. At the same time, the company’s diagnostics division — less exposed to pricing regulation — continues to serve as a stabilizing earnings contributor, reinforcing the strategic value of diversifying beyond traditional pharmaceuticals.
From a public health perspective, Roche’s sustained investment in oncology and immunology innovation supports global access to advanced therapies, though affordability remains a challenge in middle-income countries. The company has committed to maintaining tiered pricing strategies in over 100 low- and middle-income nations, a policy that has drawn both praise from NGOs and scrutiny from investor groups focused on short-term margin expansion.
As markets digest the Q1 results, the focus will shift to Roche’s ability to translate pipeline progress into sustained growth — particularly in oncology, where late-stage trials for bispecific antibodies and personalized cancer vaccines are expected to yield data in late 2026. Until then, the franc’s strength will continue to obscure the underlying momentum of one of the world’s most innovative healthcare companies.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
